He’s 69.His lawyers can drag this out for years,
Post# of 148155
Financially he would have to disgorge “ill-gotten gains” of $340,000 plus a fine of triple that amount. Big deal. Drop in the bucket for him.
His greatest jeopardy would be from a class-action shareholder suit, based on completely different grounds than his insider trading, which has nothing to do with CYDY shareholders.
We’d have to prove that he negligently or purposefully messed up the results. Then we’d have to prove that THAT was why Leronlimab was not approved. Then we’d have to prove damages. In 20 or 30 years, when that case finally reaches its culmination, shareholders MIGHT get something, whatever little is left over after legal fees.
And it’s mighty hard to get blood from a turnip, especially when a lot of people in this position shield their assets in offshore accounts.